5 results
The primary objective of the study is to evaluate the long-term safety of reslizumab at a dosage of 3.0 mg/kg every 4 weeks for approximately 24 months in pediatric and adult patients with eosinophilic asthma as assessed. The secondary objectives of…
The primary objective of this study is to determine whether reslizumab, at a dosage of 0.3 or 3.0 mg/kg administered once every 4 weeks for a total of 4 doses, is more effective than placebo in improving lung function in patients with eosinophilic…
This study aims to investigate the effect of analgetics on a functional capacity evaluation (FCE) and self reported disability in patients with CLBP.
The primary objective of this study is to determine the ability of reslizumab (110 mg) administered subcutaneously (sc) once every 4 weeks to produce a corticosteroid-sparing effect (as demonstrated by percent reduction in daily OCS use) in patients…
Primary aim:- What is the increase in hemoglobin concentration between epoetin alpha injection number three and four in patients awaiting orthopedic surgery?Secondary aim:- What is de increase in hemoglobin concentration between epoetin alpha…